http://orcid.org/0000-0002-3383-8972
Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ginenus Fekadu, Jiaqi Yao & Joyce H.S. You. (2021) A systematic review of pharmacoeconomic evaluations on oral diarylquinoline-based treatment for drug-resistant tuberculosis: from high to low burden countries. Expert Review of Pharmacoeconomics & Outcomes Research 21:5, pages 897-910.
Read now
Read now
Shankar Prinja, Gaurav Jyani, Nidhi Gupta & Kavitha Rajsekar. (2021) Adapting health technology assessment for drugs, medical devices, and health programs: Methodological considerations from the Indian experience. Expert Review of Pharmacoeconomics & Outcomes Research 21:5, pages 859-868.
Read now
Read now
Vimbayi Mutyambizi-Mafunda, Bronwyn Myers, Katherine Sorsdahl, Esther Chanakira, Crick Lund & Susan Cleary. (2021) Economic evaluations of psychological treatments for common mental disorders in low- and middle-income countries: protocol for a systematic review. Global Health Action 14:1.
Read now
Read now
Xuanqian Xie, Man Wah Yeung, Zhuoyu Wang, Myra Wang, Olga Gajic-Veljanoski, Vivian Ng & Andrei Volodin. (2020) Comparison of the expected rewards between probabilistic and deterministic analyses in a Markov model. Expert Review of Pharmacoeconomics & Outcomes Research 20:2, pages 169-175.
Read now
Read now
Articles from other publishers (40)
Fang Chen, Yunchun Long, Jiayong Yang, Kailong Zhong & Bili Liu. (2023) Economic evaluation of serplulimab plus chemotherapy as the first-line treatment of oesophageal squamous cell carcinoma in China. BMJ Open 13:12, pages e078924.
Crossref
Crossref
Gary C. Brown, Melissa M. Brown & Meg C. Monigle. (2023) Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina.
Crossref
Crossref
Mauro Brero, Christina L. Meyer, Angela Jackson‐Morris, Garrison Spencer, Elizabeth Ludwig‐Borycz, Daphne Wu, Anabel Fiorella Espinosa De Candido, Maria Isabel Ferre Eguiluz, Anabelle Bonvecchio Arenas, Jo Jewell & Rachel Nugent. (2023) Investment case for the prevention and reduction of childhood and adolescent overweight and obesity in Mexico. Obesity Reviews 24:9.
Crossref
Crossref
Nam Xuan Vo, Ngan Nguyen Hoang Le, Trinh Dang Phuong Chu, Huong Lai Pham, Khang Xuan An Dinh, Uyen Thi Thuc Che, Thanh Thi Thanh Ngo & Tien Thuy Bui. (2023) Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review. Healthcare 11:16, pages 2340.
Crossref
Crossref
Constance Nève de Mévergnies, Nick Verhaeghe, Ernst H W Koster, Chris Baeken, Yannick Vander Zwalmen & Kristof Hoorelbeke. (2023) Health Economic Evaluation of Cognitive Control Training for Depression: Key Considerations. JMIR Mental Health 10, pages e44679.
Crossref
Crossref
David D. Kim, Lauren A. Do, Patricia G. Synnott, Tara A. Lavelle, Lisa A. Prosser, John B. Wong & Peter J. Neumann. (2023) Developing Criteria for Health Economic Quality Evaluation Tool. Value in Health 26:8, pages 1225-1234.
Crossref
Crossref
Rokhsareh Ebrahimi, Mohammad Hasanzadeh, Mohammad-Reza Rashidi & Abolghasem Jouyban. (2023) Low fouling aptasensing of rivaroxaban in real samples using poly (toluidine blue) decorated by silver nanoparticle: A new platform for the cardiovascular disease analysis. Microchemical Journal 189, pages 108529.
Crossref
Crossref
Amirparviz Jamshidi, Rajabali Daroudi, Eline Aas & Davood Khalili. (2023) A cost-effectiveness analysis of risk-based intervention for prevention of cardiovascular diseases in IraPEN program: A modeling study. Frontiers in Public Health 11.
Crossref
Crossref
Filipa Sampaio, Inna Feldman, Tara A. Lavelle & Norbert Skokauskas. (2021) The cost-effectiveness of treatments for attention deficit-hyperactivity disorder and autism spectrum disorder in children and adolescents: a systematic review. European Child & Adolescent Psychiatry 31:11, pages 1655-1670.
Crossref
Crossref
Rokhsareh Ebrahimi, Abolfazl Barzegari, Reza Teimuri-Mofrad, Houman Kholafazad Kordasht, Mohammad Hasanzadeh, Maryam Khoubnasabjafari, Vahid Jouyban-Gharamaleki, Abbas Afrasiabi Rad, Nasrin Shadjou, Mohammad-Reza Rashidi, Mohammad Reza Afshar Mogaddam & Abolghasem Jouyban. (2022) Selection of Specific Aptamer against Rivaroxaban and Utilization for Label-Free Electrochemical Aptasensing Using Gold Nanoparticles: First Announcement and Application for Clinical Sample Analysis. Biosensors 12:10, pages 773.
Crossref
Crossref
Michelle K. Y. Chen, Ravi Vissapragada, Norma Bulamu, Monisha Gupta, Victoria Werth & Deshan Frank Sebaratnam. (2022) Cost-Utility Analysis of Rituximab vs Mycophenolate Mofetil for the Treatment of Pemphigus Vulgaris. JAMA Dermatology 158:9, pages 1013.
Crossref
Crossref
Gaylene Pron, Matthew Hwang, Roger Smith, Angela Cheung & Kieran Murphy. (2022) Cost-effectiveness studies of vertebral augmentation for osteoporotic vertebral fractures: a systematic review. The Spine Journal 22:8, pages 1356-1371.
Crossref
Crossref
Meghan I. Podolsky, Isabel Present, Peter J. Neumann & David D. Kim. (2022) A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional Issues. Value in Health 25:8, pages 1298-1306.
Crossref
Crossref
Siyu Ma, Natalia Olchanski, Joshua T. Cohen, Daniel A. Ollendorf, Peter J. Neumann & David D. Kim. (2022) The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies. Value in Health 25:8, pages 1336-1343.
Crossref
Crossref
David W. Matthews, Samantha Coleman, Homie Razavi & Jean‐Manuel Izaret. (2022) The Payer License Agreement, or “Netflix model,” for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition. Liver International 42:7, pages 1503-1516.
Crossref
Crossref
Filipa Sampaio, Camilla Nystrand, Inna Feldman & Cathrine Mihalopoulos. (2022) Evidence for investing in parenting interventions aiming to improve child health: a systematic review of economic evaluations. European Child & Adolescent Psychiatry.
Crossref
Crossref
James D. Chambers, Madison C. Silver, Flora C. Berklein, Joshua T. Cohen & Peter J. Neumann. (2021) Are Medical Devices Cost-Effective?. Applied Health Economics and Health Policy 20:2, pages 235-241.
Crossref
Crossref
Don Husereau, Michael Drummond, Federico Augustovski, Esther de Bekker-Grob, Andrew H. Briggs, Chris Carswell, Lisa Caulley, Nathorn Chaiyakunapruk, Dan Greenberg, Elizabeth Loder, Josephine Mauskopf, C. Daniel Mullins, Stavros Petrou, Raoh-Fang Pwu & Sophie Staniszewska. (2022) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value in Health 25:1, pages 10-31.
Crossref
Crossref
Lucas E. Nikkel, Linh Tran, Jason M. Jennings & Christopher S. Hollenbeak. (2022) Cost-Effectiveness of Preoperative Spinal Imaging Before Total Hip Arthroplasty. The Journal of Arthroplasty 37:1, pages 3-9.e1.
Crossref
Crossref
Fernanda S. Tonin, Leticia P. Leonart & Cesar Casas. 2020. Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy. Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy
1
19
.
Arman S. Walia, Randy F. Sweis, Piyush K. Agarwal, Andrew K. Kader & Parth K. Modi. (2021) Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma—A Review. Cancers 14:1, pages 73.
Crossref
Crossref
Timothy J. van Dover & David D. Kim. (2021) Do Centers for Medicare and Medicaid Services Quality Measures Reflect Cost-Effectiveness Evidence?. Value in Health 24:11, pages 1586-1591.
Crossref
Crossref
Chao Cai, Ismaeel Yunusa & Ahmad Tarhini. (2021)
Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of
BRAF V600
Variation Metastatic Melanoma
. JAMA Network Open 4:11, pages e2132262.
Crossref
Crossref
Mia Salans, Patrick Travis Courtney, Anthony Yip & James D. Murphy. (2021) Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma. Cancer Medicine 10:19, pages 6618-6626.
Crossref
Crossref
Zoe Szewczyk, Elizabeth Holliday, Brittany Dean, Clare Collins & Penny Reeves. (2021) A systematic review of economic evaluations of antenatal nutrition and alcohol interventions and their associated implementation interventions. Nutrition Reviews 79:3, pages 261-273.
Crossref
Crossref
Joan FITÉ, Emmanuel GIMENEZ, Begoña SOTO, Vicente ARTIGAS, Jose R. ESCUDERO, Sergi BELLMUNT-MONTOYA & Mireia ESPALLARGUES. (2021) Systematic review on abdominal aortic aneurysm screening cost-efficiency and methodological quality assessment. International Angiology 40:1.
Crossref
Crossref
Pasquale Cacciatore, Laurenske A. Visser, Nasuh Buyukkaramikli, Catharina P. B. van der Ploeg & M. Elske van den Akker-van Marle. (2020) The Methodological Quality and Challenges in Conducting Economic Evaluations of Newborn Screening: A Scoping Review. International Journal of Neonatal Screening 6:4, pages 94.
Crossref
Crossref
Markus Haacker, Timothy B Hallett & Rifat Atun. (2020) On time horizons in health economic evaluations. Health Policy and Planning 35:9, pages 1237-1243.
Crossref
Crossref
Moupali DasJie TingSanatan ShreayStaci Bush. (2020) Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis. Annals of Internal Medicine 173:6, pages 506-507.
Crossref
Crossref
Eva Kovacs, Xiaoting Wang, Ralf Strobl & Eva Grill. (2020) Economic evaluation of guideline implementation in primary care: a systematic review. International Journal for Quality in Health Care 32:1, pages 1-11.
Crossref
Crossref
Hansel J. Otero, Andrew J. Degnan, Nadja Kadom, Peter J. Neumann & Tara A. Lavelle. (2020) Cost-Effectiveness Analysis in Pediatric Imaging: The Evidence (or Lack Thereof) Thus Far. Journal of the American College of Radiology 17:4, pages 452-461.
Crossref
Crossref
Maddalena Centanni & Lena E. Friberg. (2020) Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors. Frontiers in Pharmacology 11.
Crossref
Crossref
Anthony J. CannonAlexandra BargiotaLiana BillingsBarnaby HuntLawrence A. LeiterSamuel MalkinMichelle Mocarski, Mattis Flyvholm RantheAlisa Schiffman & Ankur Doshi. (2020) Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets. Journal of Managed Care & Specialty Pharmacy 26:2, pages 143-153.
Crossref
Crossref
Nadja Kadom, Jason N. Itri, Anna Trofimova, Hansel J. Otero & Michal Horný. (2019) Cost-Effectiveness Analysis: An Overview of Key Concepts, Recommendations, Controversies, and Pitfalls. Academic Radiology 26:4, pages 534-541.
Crossref
Crossref
Anirban Basu & Matthew L. Maciejewski. (2019) Choosing a Time Horizon in Cost and Cost-effectiveness Analyses. JAMA 321:11, pages 1096.
Crossref
Crossref
David D. KimJoshua T. CohenJohn B. WongBabak MohitA. Mark FendrickDavid M. KentPeter J. Neumann. (2019) Targeted Incentive Programs For Lung Cancer Screening Can Improve Population Health And Economic Efficiency. Health Affairs 38:1, pages 60-67.
Crossref
Crossref
Jin A. Choi, Lina D. Song, Seulggie Choi, Sang Min Park, Jin Woo Kwon & Donghyun Jee. (2019) The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea. Medicine 98:2, pages e14026.
Crossref
Crossref
Deirdre WeymannReka PatakyDean A. Regier. (2018) Economic Evaluations of Next-Generation Precision Oncology: A Critical Review. JCO Precision Oncology:2, pages 1-23.
Crossref
Crossref
Carlos E. Rodriguez-Martinez, Monica P. Sossa-Briceño & Jose A. Castro-Rodriguez. (2018) Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review. PharmacoEconomics 36:10, pages 1165-1200.
Crossref
Crossref
Patrick M. Zueger, Varun M. Kumar, Rachel L. Harrington, Gianna C. Rigoni, Alicia Atwood, Robert J. DiDomenico & Daniel R. Touchette. (2018) Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:5, pages 520-530.
Crossref
Crossref